Bone Replacement Graft — Retained Natural Tooth — First Site in Quadrant Template

Bone replacement graft - first site in quadrant.

RMH: Medical history reviewed/updates
Vitals: BP/pulse; other vitals if indicated

Quadrant: Quadrant
Tooth: #Tooth number(s)
Defect type: Defect type

Consent: Consent/PARQ reviewed; signed/verbally obtained

Periodontal chart/radiographs: Probing/BOP/CAL and radiographs/photos as applicable

Anesthesia: Anesthetic used
Carps: Carpules/amount

Defect documentation: Tooth/site, defect type, radiographs, intraoral photo of bony defect
Regenerative materials: Graft/biologic/membrane material and amount
Closure/prognosis: Closure method and expected follow-up

Procedure:
Incisions made.
Full thickness flap elevated.
Defect debrided.
Root surface conditioned.
Graft material placed: Graft material/amount
Membrane placed: Membrane used/none
Flap repositioned for primary closure.
Sutured with: Suture material/size
Hemostasis achieved.

Complications: None or describe.

Patient tolerance: Tolerance/response.

Post-op instructions: Instructions reviewed.
Rx: Prescription or none

NV: Next visit

Documentation requirements

Regenerative perio is a documentation-heavy procedure family. The chart is the only durable record that the defect was real, the graft was placed, the materials were what was billed, and the case has a defensible regenerative goal. Per AAP regenerative-therapy guidance, ADA CDT descriptor language,'s periodontics chapter, a defensible D4263 note must contain:

• Tooth number and site — universal numbering for the grafted tooth (e.g., #19 distal). Specify the surface(s) and quadrant. One first site per quadrant per session under D4263; additional sites in the same quadrant report under D4264.
• Quadrant — UR / UL / LR / LL. The "first site in quadrant" rule is quadrant-scoped; track which quadrant has already used its D4263 in the surgical plan.
• Periodontal diagnosis and AAP staging/grading — Stage I-IV, Grade A-C, generalized vs localized. Without a specific diagnosis the regenerative indication is hard to defend.
• Defect morphology — infrabony 1-wall / 2-wall / 3-wall / combined; dehiscence; fenestration; Class II furcation (mandibular molars are the predictable furcation indication; maxillary Class II and any Class III are less predictable). Wall count drives prognosis and is what reviewers look for.
• Pre-op probing depth and clinical attachment level (CAL) at the defect site — site-specific PD and CAL in mm at the defect and adjacent sites. AAP regenerative literature defines meaningful targets as PD reduction >2 mm and CAL gain >2 mm at 6-12 month re-evaluation; document the baseline so the gain can be measured.
• Pre-op radiographs / imaging — diagnostic-quality PA(s) of the tooth and defect, vertical bitewings when applicable, and limited-FOV CBCT (D0364-D0368) when the defect is suspected to be a dehiscence/fenestration, multi-wall complex, or in a furcation requiring 3D assessment. Note imaging interpretation linked to the defect.
• Pre-op intraoral photos of the bony defect — once the flap is reflected, a photograph of the open defect is the single strongest piece of audit evidence. Many AAP-trained periodontists routinely capture pre-op flap-reflected, post-debridement, and post-graft images. The checklist explicitly calls for "intraoral photo of bony defect" as part of D4263 support.
• Medical and dental history — reviewed today; flag bisphosphonates / anti-resorptives (MRONJ risk for any oral surgical procedure, especially intravenous nitrogen-containing bisphosphonates and denosumab), anticoagulants, immunosuppression, uncontrolled diabetes (HbA1c), smoking (smokers have well-documented poorer regenerative outcomes per AAP), and history of head/neck radiation.
• Vitals — pre-op BP and pulse; many state boards and most surgical practices require these on operative visits.
• Informed consent / PARQ — risks specific to bone grafting: post-op pain and swelling, infection, graft exposure / sequestration, partial or complete graft loss, membrane exposure, recession at the surgical site, sensitivity, the possibility that the regenerative goal is not achieved and additional surgery may be needed, alternatives (extraction with implant or bridge consult, non-surgical maintenance with progression, surgical pocket reduction without grafting), no-treatment risks (continued attachment loss, mobility, eventual tooth loss). Note signed vs verbal.
• Anesthesia — agent, concentration, vasoconstrictor, technique (infiltration / block), and carpule count.
• Incision design — sulcular, intracrevicular, papilla preservation, vertical releases. Modern minimally invasive surgical technique (MIST / M-MIST) preserves the interdental papilla and is the regenerative norm; document the approach.
• Flap reflection — full-thickness mucoperiosteal; extent and adjacent teeth involved.
• Defect debridement — granulation tissue removed, root surface debrided of subgingival calculus and biofilm, defect walls visualized and confirmed (the wall count documented earlier should now be confirmed intraoperatively and re-stated if different).
• Root surface conditioning — citric acid / EDTA / tetracycline conditioning when used; many regenerative protocols include EDTA gel application to remove the smear layer prior to graft placement. AAP and contemporary regenerative literature support this step; document if performed.
• Graft material — product, manufacturer, type, and lot number — required by FDA tissue-tracking regulations for human-derived materials (allograft) and best-practice for xenograft and alloplast. Examples: "MinerOss FDBA particulate, BioHorizons, lot ##, 0.5 cc" or "Bio-Oss xenograft, Geistlich, particle size 0.25-1 mm, lot ##, 0.5 g." Include amount used.
• Biologic adjunct — if used, name and lot (e.g., rhPDGF-BB / GEM 21S, enamel matrix derivative / Emdogain, PRF / L-PRF / A-PRF, recombinant BMP-2). Many regenerative protocols pair a bone graft with a biologic to enhance outcomes; AAP position papers support this combination for select indications.
• Membrane (if used) — product and lot — resorbable collagen membranes (Bio-Gide, BioMend, OsseoGuard) are most common; non-resorbable PTFE / titanium-reinforced PTFE less so. When a membrane is placed, D4266 (resorbable) or D4267 (non-resorbable) is reported per site in addition to D4263 — both codes can be on the same claim line for the same site under AAP/ADA bundling guidance.
• Closure — primary closure achieved (the regenerative goal); flap repositioned coronally if needed; suture material, size, and pattern (e.g., "5-0 PTFE, simple interrupted x 6 + sling x 2"); knot count when relevant.
• Hemostasis — achieved; method if notable (pressure, electrosurgery for soft tissue distant from graft, hemostatic agent).
• Complications — explicit "None" or describe (excessive bleeding, perforation of sinus / nasal floor, damage to adjacent root surface, inability to achieve primary closure).
• Patient tolerance / response — tolerated well, vitals stable, no adverse events.
• Post-op instructions — soft diet, no chewing on the surgical site, no brushing the surgical site for the prescribed window (typically 2 weeks; chlorhexidine 0.12% rinse BID instead), no smoking, no straws / no spitting first 24 h, expected swelling and bruising, ice intermittent first 24 h, return precautions (uncontrolled bleeding, increasing pain after 72 h, fever, suture loss before scheduled removal, graft particle expulsion).
• Prescriptions — analgesic regimen (ibuprofen 600 mg q6h prn ± acetaminophen 500 mg alternating per current AAP and ADA pain-control guidance favoring NSAID-first protocols over routine opioids); chlorhexidine 0.12% gluconate rinse BID x 2 weeks; antibiotic per practice protocol — AAP regenerative-therapy guidance commonly includes systemic antibiotics (commonly amoxicillin 500 mg TID x 7 days, or doxycycline 100 mg BID) when allograft / xenograft / alloplast / membranes are used, though evidence for routine antibiotic prophylaxis in healthy patients is mixed.
• Re-evaluation plan — suture removal at 7-14 days; soft-tissue check at 3-4 weeks; 6-12 month re-evaluation with re-probed PD and CAL and follow-up radiograph to assess defect fill. The regenerative endpoint is what justifies the procedure.
• Provider signature and assistant initials.

Two phrases that defuse the most common audit questions: an explicit defect morphology with wall count and pre-op CAL ("3-wall infrabony defect, 7 mm PD, 9 mm CAL distal #19"), and the graft material with lot number and amount ("MinerOss cortical FDBA, 0.5 cc, lot 24A1234"). Both track ADA descriptor language and FDA tissue-tracking expectations directly.

Common denial reasons

D4263 carries meaningful dollar exposure and is one of the most reviewed periodontal codes. The most frequent reasons it is denied, downgraded, or recouped:

• Missing or weak defect documentation — chart says "infrabony defect grafted" without a wall count, pre-op PD, or pre-op CAL. The single most common denial reason on D4263 review.
• No pre-op radiograph or pre-op imaging silent on the defect — D4263 effectively requires a pre-op PA (and often vertical bitewings or limited-FOV CBCT for a furcation or complex defect) showing the bony defect. Carriers commonly request imaging on review.
• No intraoral photo of the bony defect — increasingly an expected element on review by major commercial carriers and AAP-style chart audits. Once the flap is reflected, a photograph of the open defect is the single strongest piece of audit evidence. Silence reads as a missed step.
• Graft material lot number not recorded — FDA tissue-tracking regulations and most carriers' clinical policies require the product, manufacturer, and lot number for human-derived allograft. Missing lot number can be cited as a documentation deficiency on audit.
• Defect morphology does not support regeneration — 1-wall defect, generalized horizontal bone loss, advanced (Class III) furcation, severe mobility — carrier reviewer concludes the case did not have a regenerative indication and processes at the osseous (D4260/D4261) fee schedule or denies entirely.
• D4263 billed for a socket graft / ridge preservation — that's D7953, not D4263. D4263 requires a retained natural tooth at the grafted site. Auto-rejected on tooth/site cross-check.
• D4263 billed for a graft around an implant — that's D6104 (or D7950 staged), not D4263. Different code family.
• Multiple D4263 billed in the same quadrant same DOS — only one D4263 per quadrant per session; additional sites bill D4264. Auto-rejected by quadrant edit.
• D4263 billed without an established perio diagnosis — chart shows no Stage/Grade, no probing chart, no AAP classification. The procedure is reported on a tooth with no documented periodontal disease.
• D4263 + D4260 / D4261 same DOS bundling denials — even when both are clinically indicated, some carriers bundle on automated review. Workaround is a narrative naming the resective sites (osseous) separately from the regenerative site (graft).
• D4263 + D4266 / D4267 same site denied as redundant — incorrect from the carrier; AAP and ADA bundling guidance is explicit that graft and membrane are separately reportable. Resubmit with a narrative.
• Re-graft at a previously failed site without narrative — most carriers will not pay a second D4263 on the same site without a narrative documenting the failure mode and the regenerative rationale.
• Smoker / uncontrolled diabetic without risk-factor narrative — some clinical-policy bulletins flag these patients as higher-risk for regenerative failure and require an explicit narrative addressing risk before paying.
• Default-template chart notes — identical defect morphology, wall counts, PDs, CAL, and graft volumes across multiple patients flagged as templating. Medicaid MCO and several commercial carriers run template-fingerprint review.
• Failure to schedule or document 6-12 month re-evaluation — the regenerative goal is the indication for the procedure; not following through with re-probing and follow-up imaging weakens the chart's defense if the case is later audited.
• Antibiotic prophylaxis prescribed without justification — flagged in chart audits even though it doesn't affect D4263 reimbursement directly. Routine antibiotic prophylaxis for periodontal surgery is not universally supported by the literature; document the indication.

Related templates